Australian biotech market watch 07/04/10

By Tim Dean
Wednesday, 07 April, 2010

News of a further awakening economy and the possibility of more interest rate rises has seen the All Ordinaries nudge up another 11.5 points in morning trading to 4,985, primarily driven by IT and utilities.

Health stocks are also generally up, with the Big Three making moves in recent days.

CSL (ASL:CSL) has risen, nudging $36.50 in the last week or so, and is up 31c to a nice round $36.36 today.

Cochlear (ASX:COH) up a further 76c, or 1%, to $73.31 after strong rises throughout March.

ResMed (ASX:RMD) taken a 2% dip, down 14c to $6.79, on the back of news that CEO, Kieran Gallahue, has sold 25,000 shares.

Impedimed (ASX:IPD) is also up 1% to 77c after lodging another application with the FDA to expand usage of the L-Dex U400 device, which could increase its market in the United States.

Regenerative medicine company, Mesoblast, is also up 1.5% to $2.09.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd